PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer - Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study

被引：0
|
作者：
Loibl, S.
Budczies, J.
Weichert, W.
Furlanetto, J.
Stenzinger, A.
Pfarr, N.
von Minckwitz, G.
Jackisch, C.
Schneeweiss, A.
Fasching, P.
Schmatloch, S.
Aktas, B.
Nekljudova, V.
Weber, K.
Untch, M.
Denkert, C.
机构：
[1] German Breast Grp, Neu Isenburg, Germany
[2] Charite, Berlin, Germany
[3] Univ Hosp Heidleberg, Heidelberg, Germany
[4] Sana Klinikum Offenbach, Offenbach, Germany
[5] Univ Hosp Erlangen, Erlangen, Germany
[6] Elisabeth Krankenhaus Kassel, Kassel, Germany
[7] Univ Hosp Sen, Essen, Germany
[8] Helios Kliniken Berlin Buch, Berlin, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P3-07-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-03
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
    Chai, Y.
    Jiang, M.
    Liu, J.
    He, M.
    Wang, X.
    Wang, Y.
    Yang, X.
    Wang, J.
    Xu, B.
    Li, Q.
    ANNALS OF ONCOLOGY, 2023, 34 : S327 - S327
  • [42] Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis
    Shi, Qiyun
    Xuhong, Juncheng
    Tian, Hao
    Zhang, Yi
    Jiang, Jun
    Qi, Xiaowei
    CANCER RESEARCH, 2023, 83 (05)
  • [43] The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
    Charla C. Engels
    Mandy Kiderlen
    Esther Bastiaannet
    Ronald van Eijk
    Antien Mooyaart
    Vincent T. H. B. M. Smit
    Anton J. M. de Craen
    Peter J. K. Kuppen
    Judith R. Kroep
    Cornelis J. H. van de Velde
    Gerrit Jan Liefers
    Breast Cancer Research and Treatment, 2016, 156 : 361 - 370
  • [44] The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
    Engels, Charla C.
    Kiderlen, Mandy
    Bastiaannet, Esther
    van Eijk, Ronald
    Mooyaart, Antien
    Smit, Vincent T. H. B. M.
    de Craen, Anton J. M.
    Kuppen, Peter J. K.
    Kroep, Judith R.
    van de Velde, Cornelis J. H.
    Liefers, Gerrit Jan
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (02) : 361 - 370
  • [45] Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation
    Damodaran, Senthil
    Murthy, Rashmi K.
    Nusrat, Maliha
    Saigal, Babita
    Trager, Samantha C.
    Tripathy, Debu
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2021, 81 (04)
  • [46] SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER)
    Oliveira, M.
    Villagrasa, P.
    Ciruelos, E. M.
    Gavila, J.
    Cortegoso, A.
    Henao, F.
    Vega, E.
    Salvador, J.
    Quiroga, V.
    Estevez, L. G.
    Morales, S.
    Tolosa, P.
    Salvador, F.
    Gonzalez, X.
    Saura, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S389 - S389
  • [47] Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather)
    Oliveira, Mafalda
    Villagrasa, Patricia
    Ciruelos, Eva
    Gavila, Joaquin
    Cortegoso, Alexandra
    Henao, Fernando
    Vega, Estela
    Bofill, Javier S.
    Quiroga, Vanesa
    Garcia-Estevez, Laura
    Morales, Serafin
    Tolosa, Pablo
    Celiz, Pamela
    Farre, Xavier Gonzalez
    Saura, Cristina
    CANCER RESEARCH, 2021, 81 (04)
  • [48] A prospective, open, multi-center clinical study of pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvant treatment for stage II-III HER2-positive breast cancer patients
    Shao, Bin
    Yu, Zhengyan
    Wang, Yu
    Zhao, Guangcai
    Zhou, Fei
    Wei, Ranmei
    CANCER RESEARCH, 2022, 82 (04)
  • [49] Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study.
    Chai, Yue
    Li, Qiao
    Liu, Jiaxuan
    Jiang, Mingxia
    He, Maiyue
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab
    Nishimura, Reiki
    Toh, Uhi
    Tanaka, Maki
    Saimura, Michiyo
    Okumura, Yasuhiro
    Saito, Tsuyoshi
    Tanaka, Toshihiro
    Teraoka, Megumi
    Shimada, Kazuo
    Katayama, Kazuhisa
    Koga, Toshihiro
    Kurashita, Kaname
    Hasegawa, Satoshi
    Todoroki, Hidekazu
    Kai, Yuichiro
    Ohi, Yasuyo
    Toyoshima, Satoshi
    Arima, Nobuyuki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    ONCOLOGY, 2017, 93 (01) : 51 - 61
12345